Carl Zeiss Meditec AG
XETRA:AFX

Watchlist Manager
Carl Zeiss Meditec AG Logo
Carl Zeiss Meditec AG
XETRA:AFX
Watchlist
Price: 46.62 EUR 0.52% Market Closed
Market Cap: 4.2B EUR
Have any thoughts about
Carl Zeiss Meditec AG?
Write Note

Gross Margin
Carl Zeiss Meditec AG

55.1%
Current
58%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.1%
=
Gross Profit
1.1B
/
Revenue
2.1B

Gross Margin Across Competitors

Country DE
Market Cap 4.2B EUR
Gross Margin
55%
Country US
Market Cap 199.4B USD
Gross Margin
56%
Country US
Market Cap 190.4B USD
Gross Margin
67%
Country US
Market Cap 139.9B USD
Gross Margin
64%
Country US
Market Cap 133.6B USD
Gross Margin
69%
Country IE
Market Cap 103.6B USD
Gross Margin
65%
Country US
Market Cap 66B USD
Gross Margin
45%
Country DE
Market Cap 58.2B EUR
Gross Margin
38%
Country US
Market Cap 44.6B USD
Gross Margin
79%
Country CN
Market Cap 313.1B CNY
Gross Margin
64%
Country US
Market Cap 36.2B USD
Gross Margin
41%
No Stocks Found

Carl Zeiss Meditec AG
Glance View

Market Cap
4.2B EUR
Industry
Health Care
Economic Moat
None

Carl Zeiss Meditec AG stands as a beacon in the realm of medical technology, carving a niche through its innovative solutions in ophthalmology and microsurgery. Rooted in the prestigious legacy of the Zeiss Group, this company seamlessly fuses cutting-edge technology with practical medical applications. Its headquarters in Jena, Germany, serve as the crucible for pioneering research and development endeavors, channeling expertise into products that enhance both diagnostic and surgical capabilities. The heart of its operations revolves around creating technological marvels such as optical coherence tomography (OCT) instruments and surgical microscopes, which bring precision and enhanced clarity to the medical field. Through a well-executed blend of R&D and strategic acquisitions, Carl Zeiss Meditec consistently remains at the forefront of medical innovation, ensuring it meets the ever-evolving needs of the healthcare sector. Financially, the company thrives by selling its sophisticated medical devices directly to healthcare professionals, hospitals, and clinics worldwide. Rather than merely creating instruments, Carl Zeiss Meditec's business model is deeply entwined with providing comprehensive workflow solutions and service support, ensuring that medical practitioners extract maximum utility from their investments. By offering not just products but also extensive after-sales service and maintenance, the company builds sustained relationships with its clients, fostering a cycle of trust and repeat business. In addition, its engagement in training and support services enhances user competencies, ensuring the seamless integration of its technology into everyday medical practice and underscoring its commitment to elevating healthcare standards globally. Through this multifaceted approach, Carl Zeiss Meditec solidifies its position as an indispensable ally in the medical community, both as a supplier of state-of-the-art equipment and as a provider of essential healthcare solutions.

AFX Intrinsic Value
91.75 EUR
Undervaluation 49%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.1%
=
Gross Profit
1.1B
/
Revenue
2.1B
What is the Gross Margin of Carl Zeiss Meditec AG?

Based on Carl Zeiss Meditec AG's most recent financial statements, the company has Gross Margin of 55.1%.